Methyldopa Remedica (Anhydrous Methyldopa)

• Methyldopa is used as an antihypertensive agent that acts on central sympathetic pathways to control elevated blood pressure.
• Essential hypertension: reduces systolic and diastolic pressure, helping achieve target blood pressure levels in adult patients.
• Hypertension in pregnancy: provides blood pressure control considered relatively safe for mother and fetus when other agents are unsuitable.
• Preeclampsia: assists in managing severe hypertension associated with preeclampsia, contributing to maternal and fetal outcome improvement.

• Methyldopa is metabolized to alpha‑methylnorepinephrine, which stimulates central α2‑adrenergic receptors in the medullary vasomotor center. Activation of these receptors inhibits sympathetic outflow, decreasing norepinephrine release from peripheral nerve terminals. The resulting reduction in peripheral vascular resistance and cardiac output leads to a sustained lowering of arterial blood pressure. The effect is dose‑dependent and persists with chronic administration, providing stable control of hypertension without significant reflex tachycardia.

Methyldopa may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Dizziness: sensation of light‑headedness, especially after standing.
• Headache: mild to moderate intensity.
• Fatigue: persistent tiredness not relieved by rest.
• Nausea: upset stomach sometimes with vomiting.

Serious or Rare Side Effects

• Hepatic dysfunction: elevated liver enzymes or jaundice.
• Severe hypotension: abrupt drop in blood pressure causing fainting.
• Hemolytic anemia: destruction of red blood cells leading to pallor and fatigue.
• Stevens‑Johnson syndrome: severe skin reaction with blistering and mucosal involvement.

When prescribing Methyldopa, clinicians should observe several safety considerations to minimize risk.

• Blood pressure monitoring: check BP regularly to assess therapeutic response.
• Liver function assessment: evaluate hepatic enzymes before and during therapy.
• Anemia surveillance: monitor hemoglobin and hematocrit for signs of hemolysis.
• Cardiovascular caution: use carefully in patients with existing heart block or severe coronary disease.
• Discontinuation guidance: avoid abrupt cessation to prevent rebound hypertension.
• Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Methyldopa can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• MAO inhibitors: combined use may cause hypertensive crisis.
• Clonidine: additive central antihypertensive effect leading to excessive hypotension.
• Insulin or oral hypoglycemics: may mask hypoglycemia symptoms.

Moderate Interactions (Monitor Closely)

• NSAIDs: may reduce antihypertensive effect.
• Diuretics: can enhance hypotensive response, requiring dose adjustment.
• Calcium channel blockers: may increase risk of peripheral edema.